Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1625 1635 1636 1674 1682
This examiner grants 68% of resolved cases
Brian A. Whiteman is an examiner in Art Unit 1600 of Tech Center 1600. He has managed 1168 resolved cases, providing a substantial basis for analyzing his prosecution patterns. His allowance rate is 68.4 percent, which indicates that more than half of the applications he reviews reach a grant. This 68.4 percent rate suggests a moderate but steady path to allowance for practitioners.
The interview lift for this examiner is 16.8 percent. This positive value shows that conducting an interview is a productive strategy, as it correlates with a higher likelihood of success compared to cases without an interview. Practitioners should note that the 16.8 percent lift is a significant factor in overcoming rejections. Direct engagement can be a key tool in managing the 1168 cases that constitute his professional record.
The median time to allowance is 981 days. This 981-day timeframe is an important metric for setting client expectations regarding the duration of the patent lifecycle. By combining the 68.4 percent allowance rate with the 981-day median, attorneys can better plan their prosecution strategy. These data points offer a clear view of the examination environment in this specific art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17417022 | Beta-Galactosidase Alpha Peptide as a Non-Antibiotic Selection Marker and Uses Thereof | Final Rejection | Janssen Biotech, Inc. |
| 18421647 | MODIFIED OLIGONUCLEOTIDES TARGETING SNPs | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17913100 | MICRORNAS FOR THE PREVENTION OF CLINICAL VENOUS THROMBOEMBOLIC DISEASE | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 16763827 | COMPOSITIONS AND METHODS FOR EFFICIENT GENOME EDITING | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17597995 | NDUFS2 SUBUNIT KNOCKOUT HUMAN CELL LINE | Non-Final OA | Virginia Tech Intellectual Properties Inc. |
| 17795943 | DELIVERY OF COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18417527 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | Non-Final OA | The General Hospital Corporation |
| 17612000 | DNA NANOARCHITECTURES FOR PATTERN-RECOGNIZED TARGETING OF DISEASES | Final Rejection | RENSSELAER POLYTECHNIC INSTITUTE |
| 18294680 | MODIFIED NUCLEIC ACID COMPOSITIONS AND ASSOCIATED METHODS FOR TREATMENT OF PHENYLKETONURIA | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17780600 | RNA INTERFERENCE-INDUCING NUCLEIC ACID COMPRISING 8-OXOGUANINE, MODIFIED NUCLEIC ACID BINDING TO MICRORNA COMPRISING 8-OXOGUANINE, AND USES THEREOF | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17970138 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18403862 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING OR AT RISK OF DEVELOPING A NON-PRIMARY HYPEROXALURIA DISEASE OR DISORDER | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 17985978 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | Non-Final OA | Korro Bio, Inc. |
| 17414547 | SCREENING ASSAY | Non-Final OA | The University of Bath |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy